Skip to main content
. 2023 Nov 28;13(4):401–412. doi: 10.1159/000535501

Fig. 2.

Fig. 2.

Kaplan-Meier estimates of OS in patients treated with atezolizumab + bevacizumab for ≥6 months by whether bevacizumab was skipped due to bevacizumab AESIs. AESI, adverse event of special interest; HR, hazard ratio; NE, not estimable; OS, overall survival.